
PAI to acquire Amplitude from Apax
PAI Partners has entered into exclusive negotiations to acquire a majority stake in orthopaedics manufacturer Amplitude Surgical from Apax Partners.
The firm has offered €2.15 per share and is currently drawing equity from its PAI Europe VII fund, which closed on €5bn in March 2018. Prior to the announcement, the company was trading at €1.62 per share.
Apax, which currently owns 41.4% of the listed company, would fully exit its stake, with PAI acquiring a controlling stake of 52.3%.
The company’s management team, led by CEO Olivier Jallabert, would retain stakes amounting to 11.1% at the same valuation of €2.15 per share. Management will continue to lead Amplitude.
The company reported annual sales of €88.3m and unaudited EBITDA of approximately €17.5m for the year ending on 30 June 2020. The company expects sales of €115m in the 2021 financial year.
Apax acquired the company from Weinberg Capital Partners and Initiative & Finance in a deal that valued the company in the €100-125m range. Amplitude was a portfolio company of Apax France VIII, which closed on €700m in June 2011.
It listed on Euronext Paris with a €234m market cap (at 500 cents per share) and raised €50m to pursue its international expansion in 2015. Apax retained a 44.69% stake, down from 84.91% pre-IPO.
Founded in 1997 in Valence, France, it is a provider of surgical technology market for lower-limb orthopaedics.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater